The Filing Desk

Alumis vs Ocular Therapeutix

Alumis ALMS · Ocular Therapeutix OCUL · Pharmaceuticals

Ocular Therapeutix reported revenue of $52 million in fiscal 2025, 2.2 times Alumis' $24 million in fiscal 2025. Alumis had an operating margin of -1886.9%, against -519.8% at Ocular Therapeutix. Free cash flow was −$370 million at Alumis and −$217 million at Ocular Therapeutix.

Side by side

AlumisOcular Therapeutix
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$24M$52M
Revenue growth—−18.5%
Revenue growth a year, last 5 years—24.5%
Gross margin—87.3%
Operating margin−1,886.9%−519.8%
Net margin−1,011.8%−511.9%
Free cash flow−$370M−$217M
Free cash flow margin−1,539.2%−417.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count200.0%18.3%
Last close$5.60$6.21
P/E at the last close——
Insider trades, last 12 months—bought $461,354, sold $2.8 million
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlumisOcular Therapeutix
Operating margin
Percent of revenue
AlumisOcular Therapeutix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlumisOcular Therapeutix

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alumis and Ocular Therapeutix pages.